Elsevier R&D Solutions Welcomes Four Biotech Start-Ups to the Hive
News Oct 22, 2016
Elsevier has announced that four start-up companies have been selected for The Hive, Elsevier’s new incubator project for biotech and pharmaceutical start-up firms. Arctic Pharma, Rubius Therapeutics, Reset Therapeutics and Myelo Therapeutics were selected for demonstrating their commitment to addressing areas of high needs in therapeutics. All four firms will receive complimentary training and access to Elsevier’s suite of information solutions, to empower their work and help overcome R&D bottlenecks and challenges.
Through The Hive, Elsevier will showcase the innovation that occurs in early stage drug discovery and development. “The goals of The Hive are to highlight the incredible innovation taking place outside the walls of traditional pharma companies and to celebrate the important role that small biotech start-ups play in the origin of drug discoveries,” said Alexander Van Boetzelaer, Managing Director, Elsevier R&D Solutions.
“The four companies we selected for The Hive are exceptional examples of the kind of cutting-edge research that is happening in the biotech industry. We believe that each one has the potential to drive successful pharmaceutical outcomes and improve the lives of patients. We are delighted to welcome these four companies to The Hive and look forward to sharing their stories.”
Elsevier R&D Solutions for Pharma & Life Sciences fuel research and decision-making in early stage drug discovery and development, and are used by most of the world’s leading biopharmaceutical companies. The four start-ups that are part of The Hive will be using Elsevier’s tools to support their research into the following areas:
Arctic Pharma AS is developing anti-cancer drugs by exploiting the ‘sweet tooth’ of cancer cells and their peculiar metabolic features. Key enzymes that are upregulated in cancer cell metabolism are targeted with inhibitors designed at Arctic Pharma. This supports Arctic Pharma’s development of new pharmaceuticals to combat cancer that exhibit few side effects.
Rubius Therapeutics, founded by Flagship VentureLabs, is using breakthrough science to develop an entirely new class of therapy. Red-Cell Therapeutics™ (RCTs) have the potential to treat a wide array of diseases including rare genetic disorders, metabolic conditions, cancer, autoimmune and infectious diseases.
Myelo Therapeutics is developing treatments in areas of high unmet medical needs. Its lead compound, Myelo001, is an orally applied small molecule. MyeloConcept, a phase IIa clinical trial, currently investigates the efficacy of Myelo001 in reducing the occurrence of Chemotherapy-Induced Neutropenia (CIN), a side effect of cytotoxic chemotherapy that can delay treatment.
Reset Therapeutics is a discovery-stage biopharma company developing first-in-class approaches to treating diseases by restoring the body’s natural 24-hour, or circadian, rhythms. Reset’s pipeline includes new chemical entities designed to treat Cushing’s disease, type-2 diabetes and other metabolic disorders and narcolepsy and other disorders associated with excessive daytime sleepiness.
“Our mission is to make Arctic Pharma a leader in cancer therapies that are environmentally friendly and have few side effects – access to Elsevier’s suite of programs will allow us to achieve this aim,” commented Dr. Claudia A. McDonald Bøen, CEO of Arctic Pharma. “As a small start-up company, the opportunity to be part of The Hive is significant. It will give us access to trustworthy data that will help us make better informed decisions on lead compound selections, and increase our productivity and scientific progress by reducing the time we spend searching data to find everything that is relevant.”
The products that The Hive Participants will be using include: Pathway Studio™, Reaxys ®, Reaxys ® Medicinal Chemistry, ScienceDirect, Scopus, PharmaPendium® and Embase®. The Hive will engage the wider pharma R&D community via case studies and other digital content featuring the participants; which will be widely-promoted throughout Elsevier’s online and social networks.
Researchers have figured out precisely why one drug binds to the serotonin receptor 5-HT2BR and activates it to cause heart problems while very similar drugs do not. They've also discovered why a third drug acts like a 5-HT2BR antagonist - it blocks the receptor's activity - while the very well-known similar hallucinogenic drug LSD does not.READ MORE
Each year in the U.S., at least 23,000 people die from infections caused by antibiotic resistant bacteria. Using computer modeling, researchers are developing the means to prevent some of those deaths. One way bacteria develop resistance is by producing pumps that spit out antibiotics, before they can do any damage. The researchers teased out the details of how one antibiotic pump works.READ MORE